M&A | Partnerships

The transaction includes GUIDOR bone graft substitutes known as easy-graft and calc-i-oss, and builds on the company's strategy to expand its technologies.

Over 25,000 of Theracell's licensed demineralized bone fiber products have been delivered by the company's licensee partners.

The expanded agreement with Australian Biotechnologies includes exclusive rights to market demineralized fiber grafts for Australia and New Zealand.

The company and its partners formed TrueBone3D to develop biologically active, patient-tailored bioresorbable implants enriched with ALLOB.

OssDsign expects to see revenue from Osteo3 ZP bone graft substitute putty during 2H21 following approval processes in U.S. hospitals.

Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.

Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.

Fibrinet enables safe and rapid preparation of Platelet-Rich Fibrin Membrane and Platelet-Rich Fibrin Gel from a small sample of blood at the point of care.

LifeHealthcare will sell STIMULAN and genex calcium matrices for surgical use in musculoskeletal infections, trauma, spine and foot/ankle.

The technology has shown encouraging early results for regrowth of long bone defects in patients who have lost more than six centimeters of bone.